Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Condition(s):Relapsed Classic Hodgkin Lymphoma; Refractory Classic Hodgkin LymphomaLast Updated:January 30, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Relapsed Classic Hodgkin Lymphoma; Refractory Classic Hodgkin LymphomaLast Updated:January 30, 2024Recruiting
Condition(s):Acute Myeloid LeukemiaLast Updated:August 7, 2023Active, not recruiting
Condition(s):Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaLast Updated:March 15, 2022Unknown status
Condition(s):Brain Tumor RecurrentLast Updated:November 30, 2018Completed
Condition(s):MDS; Systemic Autoimmune DiseasesLast Updated:October 4, 2022Completed
Condition(s):Breast Cancer Female; Breast Cancer InvasiveLast Updated:May 6, 2023Recruiting
Condition(s):Myelodysplastic Syndromes; MDS/MPN Crossover SyndromesLast Updated:March 12, 2024Recruiting
Condition(s):Myelodysplastic SyndromesLast Updated:February 28, 2024Not yet recruiting
Condition(s):Myelodysplastic Syndromes,Acute Myeloid LeukemiaLast Updated:June 7, 2019Unknown status
Condition(s):Acute Myeloid LeukemiaLast Updated:December 26, 2023Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.